Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| RADX | Radiopharm Theranostics | $10.86 | $6.60 | 154.93% | 20.2M | $40M | $3.50$16.25 |
| ARTV | Artiva Biotherapeutics | $4.33 | $1.03 | 31.21% | 5.9M | $81M | $1.47$11.55 |
| IMNM | Immunome | $24.59 | $5.02 | 25.65% | 205.3K | $1.8B | $5.15$25.31 |
| KYTX | Kyverna Therapeutics | $10.98 | $2.20 | 25.06% | 11.4M | $385M | $1.78$13.67 |
| ANPA | Rich Sparkle | $23.69 | $4.58 | 23.97% | 1.9K | $239M | $2.80$54.75 |
| BDRX | Biodexa Pharmaceuticals Plc | $5.52 | $0.77 | 16.21% | 3.9M | $2.9M | $3.58$92.00 |
| ASTI | Ascent Solar Technologies | $3.60 | $0.48 | 15.38% | 682.4K | $11M | $1.10$4.41 |
| FBYD | Falcon's Beyond Global | $12.95 | $1.70 | 15.11% | 1.8K | $419M | $3.62$29.02 |
| RKLZ | Tidal Trust II - Defiance Daily Target 2x Short Rklb ETF | $9.65 | $1.25 | 14.89% | 465.3K | - | $7.50$25.51 |
| QBTZ | Tidal Trust II - Defiance Daily Target 2x Short Qbts ETF | $14.70 | $1.81 | 14.04% | 716.9K | - | $8.77$32.28 |
Related Articles
Featured Article
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
Leo Miller|Aug 29, 2024
Artiva's revolutionary cell therapies could be a patient lifeline and a goldmine for investors.
Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?
Alex Carchidi|Feb 25, 2024
The market's excited for these stocks, but there's no rush to buy them.
Down 80% in 1 Day, Is There Any Hope for FibroGen Stock?
Alex Carchidi|Jul 1, 2023
Its pipeline is looking thin, and it might hit another speed bump quite soon.
Advertisement
What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?
Keith Speights|Jul 29, 2021
FDA approval of roxadustat seems unlikely.
1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences?
Jia Jie Chen|Apr 21, 2021
The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now?
This Was the Top-Performing IPO in 2020
Rick Munarriz|Dec 28, 2020
A lot of buzz-generating IPOs have more than tripled in 2020, but you probably don't know the top U.S. debutante that has soared 583% this year.
Up 1,600% In 2 Days, Is It Too Late To Buy This Hot Biotech Stock?
Zhiyuan Sun|Dec 10, 2020
Greenwich LifeSciences made investors rich overnight. Is there any growth left in this breast cancer treatment developer?
Is Red Robin Gourmet Stock a Buy?
Nicholas Rossolillo|Aug 27, 2020
Before betting on a rebound, know that Red Robin isn't exactly on solid footing.
1-800-Flowers.com Says 2020 Looks Like Everything’s Coming Up Roses
Rich Duprey|Jun 18, 2020
It looks like the florist will have a record-setting end to its fiscal year.
Red Robin's First-Quarter Loss Per Share Is 6 Times Greater Than Analysts Expected
Howard Smith|Jun 10, 2020
But the restaurant chain says sales in reopened locations are exceeding expectations.
